| Drug General Information |
| Drug ID |
D0A4XJ
|
| Former ID |
DNC001386
|
| Drug Name |
SU5402
|
| Drug Type |
Small molecular drug
|
| Indication |
Multiple myeloma [ICD9: 203; ICD10:C90]
|
Investigative |
[1]
|
|---|
| Company |
Sugen Inc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H16N2O3
|
| Canonical SMILES |
CC1=CNC(=C1CCC(=O)O)C=C2C3=CC=CC=C3NC2=O
|
| InChI |
1S/C17H16N2O3/c1-10-9-18-15(11(10)6-7-16(20)21)8-13-12-4-2-3-5-14(12)19-17(13)22/h2-5,8-9,18H,6-7H2,1H3,(H,19,22)(H,20,21)/b13-8-
|
| InChIKey |
JNDVEAXZWJIOKB-JYRVWZFOSA-N
|
| CAS Number |
CAS 215543-92-3
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7890622, 8034525, 11041561, 14800286, 26759568, 39321624, 49684200, 50917281, 53790577, 57359274, 99008168, 99437178, 99445048, 103294831, 113874309, 134340443, 134340576, 134344682, 135349716, 135610394, 135698619, 136367775, 137184213, 140077316, 143496528, 152133994, 152234912, 152258203, 152344213, 160647039, 160969610, 162011863, 162205085, 163687287, 165248398, 172919589, 174561054, 176229776, 180387005, 185969916, 187071983, 223394492, 223404372, 223554876, 223704946, 226538898, 252157173, 252160347, 252216342, 252543356
|
| Target and Pathway |
| Target(s) |
FGF-3 receptor |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Regulation of actin cytoskeleton
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Bladder cancer
|
|
Central carbon metabolism in cancer
|
|
PANTHER Pathway
|
FGF signaling pathway
|
|
Reactome
|
FGFR3 mutant receptor activation
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Bladder Cancer
|
|
Neural Crest Differentiation
|
|
Signaling by FGFR
|
| References |
| REF 1 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. |
|---|
